50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.50 (-0.21%)
DOW   29,136.51 (-0.42%)
QQQ   274.07 (-0.11%)
AAPL   151.72 (+0.63%)
MSFT   235.87 (-0.67%)
META   134.37 (-1.47%)
GOOGL   97.40 (-0.78%)
AMZN   114.35 (-0.69%)
TSLA   281.85 (+2.12%)
NVDA   123.71 (+1.17%)
NIO   17.20 (-2.38%)
BABA   77.75 (-1.47%)
AMD   66.93 (+0.95%)
T   15.72 (+0.32%)
MU   50.27 (+2.84%)
CGC   2.86 (+4.38%)
F   11.90 (-0.75%)
GE   64.39 (+0.06%)
DIS   95.92 (-2.24%)
AMC   7.46 (+9.22%)
PYPL   85.44 (+1.40%)
PFE   44.13 (+0.68%)
NFLX   223.22 (-0.38%)
S&P 500   3,647.50 (-0.21%)
DOW   29,136.51 (-0.42%)
QQQ   274.07 (-0.11%)
AAPL   151.72 (+0.63%)
MSFT   235.87 (-0.67%)
META   134.37 (-1.47%)
GOOGL   97.40 (-0.78%)
AMZN   114.35 (-0.69%)
TSLA   281.85 (+2.12%)
NVDA   123.71 (+1.17%)
NIO   17.20 (-2.38%)
BABA   77.75 (-1.47%)
AMD   66.93 (+0.95%)
T   15.72 (+0.32%)
MU   50.27 (+2.84%)
CGC   2.86 (+4.38%)
F   11.90 (-0.75%)
GE   64.39 (+0.06%)
DIS   95.92 (-2.24%)
AMC   7.46 (+9.22%)
PYPL   85.44 (+1.40%)
PFE   44.13 (+0.68%)
NFLX   223.22 (-0.38%)
S&P 500   3,647.50 (-0.21%)
DOW   29,136.51 (-0.42%)
QQQ   274.07 (-0.11%)
AAPL   151.72 (+0.63%)
MSFT   235.87 (-0.67%)
META   134.37 (-1.47%)
GOOGL   97.40 (-0.78%)
AMZN   114.35 (-0.69%)
TSLA   281.85 (+2.12%)
NVDA   123.71 (+1.17%)
NIO   17.20 (-2.38%)
BABA   77.75 (-1.47%)
AMD   66.93 (+0.95%)
T   15.72 (+0.32%)
MU   50.27 (+2.84%)
CGC   2.86 (+4.38%)
F   11.90 (-0.75%)
GE   64.39 (+0.06%)
DIS   95.92 (-2.24%)
AMC   7.46 (+9.22%)
PYPL   85.44 (+1.40%)
PFE   44.13 (+0.68%)
NFLX   223.22 (-0.38%)
S&P 500   3,647.50 (-0.21%)
DOW   29,136.51 (-0.42%)
QQQ   274.07 (-0.11%)
AAPL   151.72 (+0.63%)
MSFT   235.87 (-0.67%)
META   134.37 (-1.47%)
GOOGL   97.40 (-0.78%)
AMZN   114.35 (-0.69%)
TSLA   281.85 (+2.12%)
NVDA   123.71 (+1.17%)
NIO   17.20 (-2.38%)
BABA   77.75 (-1.47%)
AMD   66.93 (+0.95%)
T   15.72 (+0.32%)
MU   50.27 (+2.84%)
CGC   2.86 (+4.38%)
F   11.90 (-0.75%)
GE   64.39 (+0.06%)
DIS   95.92 (-2.24%)
AMC   7.46 (+9.22%)
PYPL   85.44 (+1.40%)
PFE   44.13 (+0.68%)
NFLX   223.22 (-0.38%)
NASDAQ:MBRX

Moleculin Biotech - MBRX Stock Forecast, Price & News

$1.14
-0.03 (-2.16%)
(As of 09/27/2022 02:04 PM ET)
Add
Compare
Today's Range
$0.95
$1.14
50-Day Range
$1.15
$1.90
52-Week Range
$1.02
$3.08
Volume
2,650 shs
Average Volume
175,402 shs
Market Capitalization
$32.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Moleculin Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,239.3% Upside
$15.00 Price Target
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Moleculin Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.02) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

894th out of 1,071 stocks

Pharmaceutical Preparations Industry

425th out of 531 stocks

MBRX stock logo

About Moleculin Biotech (NASDAQ:MBRX) Stock

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Stock News Headlines

StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)
Moleculin Biotech GAAP EPS of -$0.24
Moleculin Biotech Reports Q1 Result
/C O R R E C T I O N -- Moleculin Biotech, Inc./
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Company Calendar

Last Earnings
8/15/2022
Today
9/27/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBRX
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+1,221.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.76 per share

Miscellaneous

Free Float
27,549,000
Market Cap
$32.47 million
Optionable
Not Optionable
Beta
1.77

Key Executives

  • Mr. Walter V. Klemp (Age 62)
    Founder, Chairman, Pres & CEO
    Comp: $891.66k
  • Mr. Jonathan P. Foster CPA (Age 58)
    Exec. VP & CFO
    Comp: $611.2k
  • Dr. Donald H. Picker Ph.D. (Age 76)
    Chief Scientific Officer
    Comp: $479.87k
  • Dr. Waldemar Priebe Ph.D.
    Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP (Age 70)
    M.D., F.A.C.P., Chief Medical Officer of Annamycin
  • Dr. John Paul Waymack M.D. (Age 70)
    Sc.D., Sr. Chief Medical Officer
  • Dr. Sandra L. Silberman M.D. (Age 67)
    Ph.D., Chief Medical Officer of New Products
  • Dr. Wolfram C. M. Dempke M.B.A.
    M.D., Ph.D., European Chief Medical Officer
  • Ms. Jacqueline Northcut (Age 60)
    Consultant
  • Mr. Louis Ploth Jr. (Age 68)
    Independent Advisor













MBRX Stock - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings
or view top-rated stocks.

What is Moleculin Biotech's stock price forecast for 2022?

1 Wall Street analysts have issued 1-year price objectives for Moleculin Biotech's stock. Their MBRX share price forecasts range from $14.00 to $16.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,193.1% from the stock's current price.
View analysts price targets for MBRX
or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2022?

Moleculin Biotech's stock was trading at $1.86 on January 1st, 2022. Since then, MBRX shares have decreased by 37.6% and is now trading at $1.16.
View the best growth stocks for 2022 here
.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our MBRX earnings forecast
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) released its quarterly earnings data on Monday, August, 15th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01.

When did Moleculin Biotech's stock split?

Moleculin Biotech's stock reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

Who are Moleculin Biotech's major shareholders?

Moleculin Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.31%) and Walker Asset Management LLC (0.07%).
View institutional ownership trends
.

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.16.

How much money does Moleculin Biotech make?

Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $33.19 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.

This page (NASDAQ:MBRX) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.